NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Serotonergic psychedelics delay resting state neurovascular coupling dynamics
This brain imaging analysis (s=2, n=32) found that LSD and DMT slowed blood-flow responses in brain regions linked to serotonin receptors during rest. Correcting for these vascular effects improved detection of drug-r...
Context Shapes Alpha-Band Electrophysiological Signatures Under Psilocybin
This EEG preprint compared baseline with 19 mg oral psilocybin in healthy adults (n=56 for rest, meditation and music; n=53 for movie viewing). Alpha power and connectivity generally fell at rest, while structured con...
American Trickster: The Hidden Lives of Carlos Castaneda
A new biography by Ru Marshall examines the long shadow that hoaxer Carlos Castaneda cast on psychedelics and new age spirituality. The post American Trickster: The Hidden Lives of Carlos Castaneda first appeared on L...
Inner Landscapes: Salvia Divinorum
An interview with Christopher Solomon on healing, embodiment, and harm reduction
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered…
Longitudinal peripheral DNA methylation remodeling following ketamine-assisted psychotherapy in major depressive disorder
This longitudinal study (n=10) examined changes in buccal DNA methylation in adults with major depressive disorder receiving three sessions of intranasal ketamine alongside structured psychotherapy. Depressive symptom...
Baseline Response Criterion and Changes in Emotional Bias as Markers of Esketamine Response in Treatment-Resistant Depression
This study (n=53) compared emotional face processing in people with treatment-resistant depression and healthy controls before and during 4 weeks of esketamine treatment. A lower baseline response criterion was associ...
NRx Pharmaceuticals received an FDA review letter requesting only minor labelling changes for preservative-free ketamine NRX-100 ahead of the 10 November 2026 GDUFA goal date.
The FDA requested minor label changes and submission of labels using NRX-100’s proprietary product name, which remains under review. NRx Pharmaceuticals is completing final manufacturing process validation runs and ai...
Longitudinal peripheral DNA methylation remodeling following ketamine-assisted psychotherapy in major depressive disorder
This longitudinal study (n=10) examined changes in buccal DNA methylation in adults with major depressive disorder receiving three sessions of intranasal ketamine alongside structured psychotherapy. Depressive symptom...
Baseline Response Criterion and Changes in Emotional Bias as Markers of Esketamine Response in Treatment-Resistant Depression
This study (n=53) compared emotional face processing in people with treatment-resistant depression and healthy controls before and during 4 weeks of esketamine treatment. A lower baseline response criterion was associ...
The Psychedelic Practitioner Issue 7: Preparedness (Systems)
Indigenous People’s Day Ain’t Over Yet
And other parties happening in New York this week after Horizons: Perspectives on Psychedelics. [...] Read More...
Why You Should Not Subscribe to the Metropolitan Review
The endless upward fail of the white male elite in America
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
LONDON & JERSEY CITY, N.J., October 14, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today…
Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Net…
This qualitative study (n=4) explored former psychedelic-trial participants’ experiences of recruitment, preparation, dosing, integration and study ending. Participants said communication, staff relationships, uncerta...